Wells Fargo & Company Annovis Bio, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 8,801 shares of ANVS stock, worth $48,933. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,801
Previous 8,800
0.01%
Holding current value
$48,933
Previous $164,000
36.59%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA358KShares$1.99 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$1.39 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$542,8170.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$403,6670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$393,5970.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $45.4M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...